India Pharma Outlook Team | Tuesday, 16 June 2026
The bowel disease treatment race is gaining momentum after Spyre Therapeutics reported positive results from a mid-stage clinical trial of its experimental ulcerative colitis drug, SPY002.
The latest data showed that the therapy significantly reduced inflammation in patients with moderate-to-severe ulcerative colitis, marking another milestone for the company as competition intensifies in the inflammatory bowel disease market.
The bowel disease treatment race has attracted major interest from drug developers in recent years, particularly around therapies targeting TL1A, a protein linked to inflammation in the digestive tract.
Spyre’s new findings add to growing evidence that TL1A-focused treatments could offer a new option for patients who do not respond adequately to existing medicines.
Spyre Therapeutics said SPY002 achieved the primary endpoint in a Phase 2 clinical trial involving patients with moderate-to-severe ulcerative colitis. After 12 weeks of treatment, the drug reduced disease severity by 10.7 points on a microscopic inflammation scoring system used to evaluate tissue damage in the colon.
The trial also delivered encouraging secondary outcomes:
Clinical remission is considered a key measure in ulcerative colitis research because it reflects meaningful improvement in symptoms and disease activity. Endoscopic improvement indicates that doctors observed reduced inflammation during colon examinations.
Also Read: Key Trends Reshaping Nutraceutical Contract Manufacturing in India
The positive results come as several pharmaceutical and biotechnology companies are developing drugs aimed at blocking TL1A. Researchers believe the protein plays an important role in driving inflammation associated with inflammatory bowel diseases such as ulcerative colitis and Crohn’s disease.
Ulcerative colitis is a chronic condition that causes inflammation and ulcers in the lining of the colon. Patients often experience symptoms including abdominal pain, diarrhea, rectal bleeding, fatigue, and weight loss. While several treatment options are available, many patients fail to achieve long-term disease control or lose response over time.
The latest findings strengthen the case for TL1A inhibitors as a potential new treatment class in the rapidly evolving inflammatory bowel disease market.
The SPY002 study is part of Spyre’s broader Phase 2 platform trial evaluating multiple drug candidates, including SPY001, SPY002, and SPY003, both as standalone therapies and in combination approaches.
The company had previously reported positive data from its SPY001 program earlier this year. In that study, 40% of patients achieved clinical remission, while 51% experienced endoscopic improvement.
Together, the results from SPY001 and SPY002 strengthen Spyre’s position as it advances its pipeline of next-generation treatments for inflammatory bowel disease. Positive outcomes from ongoing studies could support larger late-stage clinical trials, which would be required before seeking regulatory approval.
Spyre Therapeutics is a clinical-stage biotechnology company focused on developing treatments for inflammatory bowel diseases, including ulcerative colitis and Crohn’s disease. The company is building a portfolio of therapies designed to target TL1A and other pathways involved in chronic intestinal inflammation.
.jpg)
